Method for monitoring resting and activated platelets in unfixed blood samples
AssigneeSurroMed, Inc.
InventorsTimothy L. Wyant, Paul A. Raju, Aaron B. Kantor
Life of this patent
Estimating the term…
Abstract
The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.
Claims50
A method for measuring the amount of a platelet surface protein in a sample comprising platelets, comprising the steps of:
- (a) contacting the sample with a platelet stabilizing composition comprising an anticoagulant and at least one platelet activation inhibitor;
- (b) incubating the sample with a labeled compound having specific affinity for the platelet surface protein;
- and
- (c) detecting labeled compound bound to platelets by cytometry, whereby the amount of the platelet surface protein may be measured.
A method for measuring the amount of a platelet surface protein in a sample comprising platelets, comprising the steps of:
- (a) contacting the sample with a platelet stabilizing composition comprising an anticoagulant and at least one platelet activation inhibitor;
- (b) incubating the sample with a labeled compound having specific affinity for the platelet surface protein and a platelet stimulating factor;
- and
- (c) detecting labeled compound bound to platelets by cytometry, whereby the amount of the platelet surface protein may be measured.
A kit useful for measuring the amount of a platelet surface protein in a sample comprising platelets, the kit comprising a first container comprising a labeled compound, a second container comprising a collection tube containing a platelet stabilizing composition;
- and a third container comprising a buffered solution.
A method of reducing background fluorescence in microvolume laser scanning cytometry analysis of a sample, comprising the steps of:
- (a) contacting a sample with a platelet stabilizing composition comprising citrate, adenosine, theophylline and dipyridamole;
- and
- (b) incubating the sample with an antibody labeled with fluorescent dye, the antibody having specific affinity for an element of the sample;
- and
- (c) detecting bound antibody microvolume laser scanning cytometry.
Dependencies are inferred from the claim text.